Eyad Y Elhamadany
Overview
Explore the profile of Eyad Y Elhamadany including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
11
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zahran E, Zahran E, Elfoly E, Elhamadany E, Hemied M, Elsayed T, et al.
Chem Biodivers
. 2025 Jan;
:e202402847.
PMID: 39853998
Mucormycosis, a life-threatening fungal infection caused by Mucorales, affects immunocompromised patients, especially SARS-CoV-2 ones. Existing antifungal therapies, like amphotericin B, have serious health risks. The current study reviews the literature...
2.
Abu-Baih R, Ibrahim M, Elhamadany E, Abu-Baih D
Int Immunopharmacol
. 2024 May;
135:112336.
PMID: 38801809
IIrbesartan (IRB), an angiotensin II type 1 receptor (AT1R) antagonist, has been widely employed in the medical field for its effectiveness in managing hypertension. However, there have been no documented...
3.
Mohyeldin R, Alaaeldin R, Sharata E, Attya M, Elhamadany E, Fathy M
Life Sci
. 2023 Oct;
334:122210.
PMID: 37883863
Aim: Sepsis is a serious inflammatory response to infection with an annual incidence rate of >48 million cases and 11 million fatalities worldwide. Furthermore, sepsis remains the world's fifth-greatest cause...
4.
Alaaeldin R, Abdel-Rahman I, Ali F, Bekhit A, Elhamadany E, Zhao Q, et al.
Molecules
. 2022 Nov;
27(22).
PMID: 36432094
Fluoroquinolones (FQs) are synthetic broad-spectrum antimicrobial agents that have been recently repurposed to anticancer candidates. Designing new derivatives of FQs with different moieties to target DNA topoisomerases could improve their...